Literature DB >> 30066404

Structural basis for prolidase deficiency disease mechanisms.

Piotr Wilk1,2, Monika Uehlein1, Rafal Piwowarczyk1, Holger Dobbek2, Uwe Mueller1, Manfred S Weiss1.   

Abstract

Prolidase is a metallopeptidase that cleaves iminodipeptides containing a proline (Pro) or hydroxyproline (Hyp) residue at their C-terminal end. The disease prolidase deficiency (PD) is a rare recessive human disorder characterized by reduced prolidase activity. PD manifests itself by a wide range of severe clinical symptoms, most commonly as skin ulceration, recurrent infections of the respiratory tract, and mental retardation. Several mutations in the PEPD gene have been identified that are responsible for the loss or the reduction of prolidase activity. In contrast, the structural basis of enzyme inactivation has so far remained elusive. In this study, we present high resolution crystal structures of a number of human prolidase (HsProl) variants, in which single amino acids are either substituted by others or deleted. The observed implications of the mutations on the three-dimensional structure of HsProl are reported and discussed and related to their enzymatic activity. The resulting structures may be divided into four groups depending on the presumed effect of the corresponding mutations on the reaction mechanism. The four possible inactivation mechanisms, which could be elucidated, are disruption of the catalytic Mn2 (OH- )-center, introduction of chain disorder along with the displacement of important active site residues, rigidification of the active site, and flexibilization of the active site. DATABASE: All refined structure coordinates as well as the corresponding structure factor amplitudes have been deposited in the PDB under the accession numbers 5MBY, 5MBZ, 5MC0, 5MC1, 5MC2, 5MC3, 5MC4, 5MC5, 6H2P, 6H2Q.
© 2018 Federation of European Biochemical Societies.

Entities:  

Keywords:  disease mechanism; human prolidase; metalloprotease; prolidase deficiency; protein crystallography

Mesh:

Substances:

Year:  2018        PMID: 30066404     DOI: 10.1111/febs.14620

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  4 in total

1.  Ulceration in Prolidase Deficiency: Successful Treatment with Anticoagulants.

Authors:  Kira Süßmuth; Dieter Metze; Ana-Maria Muresan; Kai Lehmberg; Udo Zur Stadt; Carsten Speckmann; Julien Heinrich Park; Thorsten Marquardt; Vinzenz Oji; Tobias Goerge
Journal:  Acta Derm Venereol       Date:  2020-01-07       Impact factor: 3.875

Review 2.  Current Understanding of the Emerging Role of Prolidase in Cellular Metabolism.

Authors:  Magdalena Misiura; Wojciech Miltyk
Journal:  Int J Mol Sci       Date:  2020-08-17       Impact factor: 5.923

Review 3.  Clinical Genetics of Prolidase Deficiency: An Updated Review.

Authors:  Marta Spodenkiewicz; Michel Spodenkiewicz; Maureen Cleary; Marie Massier; Giorgos Fitsialos; Vincent Cottin; Guillaume Jouret; Céline Poirsier; Martine Doco-Fenzy; Anne-Sophie Lèbre
Journal:  Biology (Basel)       Date:  2020-05-21

4.  Prolidase deficiency, a rare inborn error of immunity, clinical phenotypes, immunological features, and proposed treatments in twins.

Authors:  Nora Alrumayyan; Drew Slauenwhite; Sarah M McAlpine; Sarah Roberts; Thomas B Issekutz; Adam M Huber; Zaiping Liu; Beata Derfalvi
Journal:  Allergy Asthma Clin Immunol       Date:  2022-02-23       Impact factor: 3.406

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.